Acrivon Therapeutics, Inc. Common Stock (ACRV) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRV trades at $1.76 with a market cap of $70.62M and a P/E ratio of -0.85. ACRV moved +10.00% today. Year to date, ACRV is -23.14%; over the trailing twelve months it is +40.80%. Its 52-week range spans $1.05 to $8.74. Analyst consensus is strong buy with an average price target of $11.20. Rallies surfaces ACRV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Acrivon Preclinical Data Showcase ACR-368 and ACR-2316 Synergies with PD-L1 and ADC Topo1: Acrivon will present three posters at AACR showing that ACR-368 synergized with anti-PD-L1 checkpoint inhibition and a Topo 1 ADC payload, while ACR-2316 combined with PD-L1 blockade produced complete tumor regression with durable immune memory. The preclinical data support frontline clinical development of ACR-368 and ACR-2316 in combinations with immune checkpoint inhibitors and ADC Topo 1 payload therapies.
| Metric | Value |
|---|---|
| Price | $1.76 |
| Market Cap | $70.62M |
| P/E Ratio | -0.85 |
| EPS | $-2.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.74 |
| 52-Week Low | $1.05 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-77.91M |
| Gross Margin | 0.00% |
6 analysts cover ACRV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.20.